Behçet's disease

Current Treatment Options in Neurology

Volumn 13, Issue 3, 2011, Pages 290-310

  Akman Demir, Gulsen ^a   Saip, Sabahattin ^b   Siva, Aksel ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA INTERFERON; ANTICOAGULANT AGENT; AZATHIOPRINE; CARBAMAZEPINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; GLUCOCORTICOID; HEPARIN FRACTION; INFLIXIMAB; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 1BETA ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREDNISOLONE; PREDNISONE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; ACUTE DISEASE; AGRANULOCYTOSIS; ALLERGIC REACTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ANOREXIA; ANXIETY DISORDER; APHTHOUS ULCER; APLASTIC ANEMIA; ARTERITIS; ARTERY DISEASE; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; ASEPTIC NECROSIS; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEHCET DISEASE; BLINDNESS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN EDEMA; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL SINUS THROMBOSIS; CHILL; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTUSION; COST EFFECTIVENESS ANALYSIS; CUSHINGOID SYNDROME; DEMYELINATING NEUROPATHY; DIARRHEA; DIET THERAPY; DIGESTIVE SYSTEM INJURY; DISEASE CONTROL; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPEPSIA; EEG ABNORMALITY; ERYTHEMA NODOSUM; EYE DISEASE; EYE INFLAMMATION; FATIGUE; FEMALE INFERTILITY; FEVER; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENITAL ULCER; GINGIVA HYPERPLASIA; GLUCOSE BLOOD LEVEL; GRANULOCYTOPENIA; HAIR LOSS; HEADACHE; HEMORRHAGIC CYSTITIS; HIP DISEASE; HIRSUTISM; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; INFECTION RATE; INFECTION RESISTANCE; INJECTION SITE REACTION; INSOMNIA; INTRAOCULAR PRESSURE ABNORMALITY; KIDNEY DISEASE; KINESIOTHERAPY; LEUKOPENIA; LIBIDO DISORDER; LIFESTYLE MODIFICATION; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MAINTENANCE THERAPY; MALAISE; MALE INFERTILITY; MENINGOENCEPHALITIS; MOOD DISORDER; MOUTH ULCER; MULTIPLE SCLEROSIS; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; PHLEBOGRAPHY; PHYSIOTHERAPY; POLYNEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PSORIASIS; PSYCHOSIS; RASH; RECOMMENDED DRUG DOSE; RETINA VASCULITIS; RHEUMATOID ARTHRITIS; SEDATION; SEIZURE; SIDE EFFECT; SKIN DEFECT; SKIN MANIFESTATION; SMELLING DISORDER; SPEECH THERAPY; SWEATING; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; TUBERCULOSIS; URTICARIA; UVEITIS; UVEORETINITIS; VASCULAR DISEASE; VASCULITIS; VEIN THROMBOSIS; VOMITING; WEIGHT GAIN;

EID: 79955841439     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-011-0120-2     Document Type: Article

References (73)

1. International Study Group for Behcet's Disease 1990 Criteria for diagnosis of Behcet's disease Lancet 335 1078 80
2. Direskeneli H, Saruhan-Direskeneli G. Disease mechanisms. In: YazIcI Y, YazIcI H, editors. Behçet's syndrome. Springer; 2010. p. 243-64. This chapter is a very comprehensive and updated review on pathogenic disease mechanisms, summarizing all the views and related findings in Behçet's disease.
3. A Gul 2005 Behcet's disease as an autoinflammatory disorder Curr Drug Targets Inflamm Allergy 4 81 3 15720240 10.2174/1568010053622894 (Pubitemid 40584857)
4. T Sakane M Takeno N Suzuki G Inaba 1999 Behcet's disease N Engl J Med 341 1284 91 10528040 10.1056/NEJM199910213411707 1:STN:280:DyaK1Mvkt1aktg%3D%3D (Pubitemid 29489745)
5. Demirkesen C, Öz B, Göksel S. Behçet's disease: pathology. In: YazIcI Y, YazIcI H, editors. Behçet's syndrome. Springer; 2010. p. 215-41. This chapter presents an extensive review of the pathology of Behçet's disease in general, with special emphasis on neuropathologic changes.
6. S Saip A Siva A Altintas, et al. 2005 Headache in Behcet's syndrome Headache 45 911 9 15985109 10.1111/j.1526-4610.2005.05160.x (Pubitemid 41045369)
7. E Aykutlu B Baykan G Akman-Demir B Topcular M Ertas 2006 Headache in Behcet's disease Cephalalgia 26 180 6 16426273 10.1111/j.1468-2982.2005.01017.x 1:STN:280:DC%2BD28%2FjvFSruw%3D%3D
8. P Serdaroglu H Yazici C Ozdemir, et al. 1989 Neurologic involvement in Behcet's syndrome. A prospective study Arch Neurol 46 265 9 2919979 1:STN:280:DyaL1M7kvFCksA%3D%3D (Pubitemid 19070223)
9. E Kural-Seyahi I Fresko N Seyahi, et al. 2003 The long term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center Medicine (Baltimore) 82 60 76 10.1097/00005792-200301000-00006 (Pubitemid 36139801)
10. G Akman-Demir P Serdaroglu B Tasci 1999 Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients Brain 122 2171 81 10545401 10.1093/brain/122.11.2171
11. A Siva OH Kantarci S Saip, et al. 2001 Behçet's disease: diagnostic & prognostic aspects of neurological involvement J Neurol 248 95 103 11284141 10.1007/s004150170242 1:STN:280:DC%2BD3Mvit1erug%3D%3D (Pubitemid 32245418)
12. A Al-Araji DP Kidd 2009 Neuro-Behcet's disease: epidemiology, clinical characteristics, and management Lancet Neurol 8 192 204 19161910 10.1016/S1474-4422(09)70015-8 This article is an extensive, literature-based, comprehensive review on neuro-Behçet disease
13. A Siva S Saip 2009 The spectrum of nervous system involvement in Behcet's syndrome and its differential diagnosis J Neurol 256 513 29 19444529 10.1007/s00415-009-0145-6 This article is another comprehensive and updated review of neuro-Behçet disease and its differential diagnosis
14. N Kocer C Islak A Siva, et al. 1999 CNS involvement in neuro-Behcet's syndrome: an MR study Am J Neuroradiol 20 1015 24 10445437 1:STN:280: DyaK1Mznt1Kjuw%3D%3D (Pubitemid 29536207)
15. G Akman-Demir S Bahar O Coban B Tasci P Serdaroglu 2003 Cranial MRI in Behcet's disease: 134 examinations of 98 patients Neuroradiology 45 851 9 14557904 10.1007/s00234-003-1102-1 1:STN:280:DC%2BD3srntFSgsQ%3D%3D (Pubitemid 38072254)
16. O Coban S Bahar G Akman-Demir, et al. 1999 Masked assessment of MRI findings: is it possible to differentiate neuro-Behcet's disease from other central nervous system diseases? Neuroradiology 41 255 60 10344509 10.1007/s002340050742 1:STN:280:DyaK1M3nsVejtA%3D%3D (Pubitemid 29195259)
17. N Yesilot M Mutlu O Gungor, et al. 2007 Clinical characteristics and course of spinal cord involvement in Behcet's disease Eur J Neurol 14 729 37 17594327 10.1111/j.1468-1331.2007.01754.x 1:STN:280:DC%2BD2sznvVWgsw%3D%3D (Pubitemid 47012165)
18. B Wechsler M Vidailhet MG Bousser, et al. 1992 Cerebral venous sinus thrombosis in Behcet's disease: long term follow up of 25 cases Neurology 42 614 8 1549224 1:STN:280:DyaK387psFCksw%3D%3D
19. N Yesilot S Bahar S Yilmazer, et al. 2009 Cerebral venous thrombosis in Behcet's disease compared to those associated with other etiologies J Neurol 256 1134 42 19280104 10.1007/s00415-009-5088-4 1:STN:280:DC%2BD1MvnsVKhtA%3D%3D This comparative article, which is based on a large series of patients with cerebral venous sinus thrombosis due both to Behçet's disease and non-Behcet's disease, outlines the differences between these conditions
20. M Kürtüncü E Tuzun M Pehlivan, et al. 2008 Clinical patterns and treatment effect on neuro-Behcet's disease: analysis of 351 patients Clin Exp Rheumatol 26 Suppl 50 S43
21. A Siva I Fresko 2000 Behcet's disease Curr Treat Options Neurol 2 435 47 11096769 10.1007/s11940-000-0042-x
22. G Hatemi A Silman D Bang, et al. 2008 EULAR Expert Committee. EULAR recommendations for the management of Behcet's disease Ann Rheum Dis 67 1656 62 18245110 10.1136/ard.2007.080432 1:CAS:528:DC%2BD1MXjs1Oitg%3D%3D
23. G Hatemi A Silman D Bang, et al. 2009 Management of Behcet's disease: a systematic literature review for the European league against rheumatism evidence-based recommendations Ann Rheum Dis 68 1528 34 18420940 10.1136/ard.2008.087957 1:CAS:528:DC%2BD1MXhtlKqtbnP This systematic literature review for the EULAR evidence-based recommendations for the management of Behçet's disease shows limited evidence for the treatment of the disease in general and the lack of evidence-based treatment for vascular, gastrointestinal, and neurologic involvement
24. H Yazici H Pazarli CG Barnes, et al. 1990 A controlled trial of azathioprine in Behcet's syndrome N Engl J Med 322 281 5 2404204 10.1056/NEJM199002013220501 1:STN:280:DyaK3c7hsVegtQ%3D%3D (Pubitemid 20046329)
25. V Hamuryudan Y Ozyazgan N Hizli, et al. 1997 Azathioprine in Behcet's syndrome: effects on long term prognosis Arthritis Rheum 40 769 74 9125262 10.1002/art.1780400425 1:CAS:528:DyaK2sXivVehtrs%3D (Pubitemid 27157585)
26. A Borhani Haghighi A Safari 2008 Anti-tumor necrotic factor antibody for treatment of neuro-Behcet's disease, a case report Clin Neurol Neurosurg 110 315 6 18053588 10.1016/j.clineuro.2007.10.005 1:STN:280:DC%2BD1c7lsFKntQ%3D%3D (Pubitemid 351305082)
27. H Kikuchi K Aramaki S Hirohata 2008 Effect of infliximab in progressive neuro-Behcet's syndrome J Neurol Sci 272 99 105 18550081 10.1016/j.jns.2008.05. 002 1:CAS:528:DC%2BD1cXpt1Kiurg%3D
28. A Al Araji A Siva S Saip, et al. 2010 Treatment of neuro-Behcet's disease with infliximab. An international multicentre case series of 18 patients Clin Exp Rheumatol 28 Suppl 60 S119 This multicenter, observational case series based on experience with treatment of neuro-Behcet's disease with infliximab shows favorable results
29. JD O'Duffy DM Robertson NP Goldstein 1984 Chlorambucil in the treatment in the treatment of uveitis and meningoencephalitis of Behcet's disease Am J Med 76 75 84 6691363 10.1016/0002-9343(84)90753-8 (Pubitemid 14216363)
30. S Hirohata H Suda T Hashimoto 1998 Low dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease J Neurol Sci 159 181 5 9741405 10.1016/S0022-510X(98)00165-8 1:CAS:528:DyaK1cXltFajtb8%3D (Pubitemid 28384527)
31. H Kikuchi K Aramaki S Hirohata 2003 Low dose methotrexate for progressive neuro-Behcet's disease. A follow up study for 4 years Adv Exp Med Biol 528 575 8 12918768 10.1007/0-306-48382-3-117 1:CAS:528:DC%2BD3sXnsFersbc%3D
32. S Kotake K Higashi K Yoshikawa, et al. 1999 Central nervous system symptoms in patients with Behcet's disease receiving cyclosporine therapy Ophthalmology 106 586 9 10080218 10.1016/S0161-6420(99)90120-3 1:STN:280:DyaK1M7nvVejsQ%3D%3D (Pubitemid 30191596)
33. I Kotter I Gunaydin M Batra, et al. 2006 CNS involvement occurs more frequently in patients with Behcet's disease under cyclosporine A than under other medications. Results of a retrospective analysis of 117 cases Clin Rheumatol 25 482 6 16261281 10.1007/s10067-005-0070-8 (Pubitemid 44137619)
34. G Akman-Demir O Ayranci M Kurtuncu, et al. 2008 Cyclosporine for Behcet's uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 26 S84 90 19026121 1:STN:280:DC%2BD1cjmtVCitQ%3D%3D
35. R Tunc S Saip A Siva H Yazici 2004 Cerebral venous thrombosis is associated with major vessel disease in Behcet's syndrome Ann Rheum Dis 63 1693 4 15547099 10.1136/ard.2003.018515 1:STN:280:DC%2BD2crntl2rsQ%3D%3D (Pubitemid 39573708)
36. JD O'Duffy NP Goldstein 1976 Neurologic involvement in seven patients with Behcet's disease Am J Med 61 170 8 952291 10.1016/0002-9343(76)90166-2
37. D Bang 1997 Treatment of Behcet's disease Yonsei Med J 38 401 10 9509910 1:CAS:528:DyaK1cXhvVeiur4%3D (Pubitemid 28117054)
38. C Mat S Yurdakul S Uysal, et al. 2006 A double blind trial of depot corticosteroids in Behcet's syndrome Rheumatology 45 348 52 16263779 10.1093/rheumatology/kei165 1:CAS:528:DC%2BD28Xhs1Sktr0%3D (Pubitemid 43372853)
39. S Kiziltas N Imeryuz T Gurcan, et al. 1998 Corticosteroid therapy augments gastroduodenal permeability to sucrose Am J Gastroenterol 93 2420 5 9860402 1:CAS:528:DyaK1MXhs1Ghsw%3D%3D (Pubitemid 29018548)
40. E Aktulga M Altac A Muftuoglu, et al. 1980 A double blind study of colchicine in Behcet's disease Haematologica 65 399 402 6778795 1:STN:280:DyaL3M%2Fpt1Sjtg%3D%3D (Pubitemid 11254772)
41. S Yurdakul C Mat Y Ozyazgan, et al. 1998 A double blind study of colchicines in Behcet's syndrome Arthritis Rheum 41 Suppl S356
42. C Confavreux P Saddier J Grimaud, et al. 1996 Risk of cancer from azathioprine therapy in multiple sclerosis: a case control study Neurology 46 1607 12 8649558 1:STN:280:DyaK283kvV2ktQ%3D%3D
43. D Ben Ezra E Cohen T Chajeck, et al. 1988 Evaluation of conventional therapy versus cyclosporin A in Behcet's syndrome Transplant Proc 20 Suppl 4 136 43 1:STN:280:DyaL1c3kvFWgsQ%3D%3D
44. Y Ozyazgan S Yurdakul H Yazici, et al. 1992 Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial Br J Ophthalmol 4 241 3 10.1136/bjo.76.4.241
45. K Masuda A Nakajima A Urayama, et al. 1989 Double masked trial of cyclosporine versus colchicines and long term open study of cyclosporine in Behçet's disease Lancet 1 8647 1093 6 2566048 10.1016/S0140-6736(89) 92381-7 1:STN:280:DyaL1M3jslGrsg%3D%3D (Pubitemid 19128039)
46. Assad-Khalil SH. Low dose cyclosporine in Behcet's disease: follow up controlled study with emphasis on extraocular manifestations and neuro-Behcet's disease. In: O'Duffy JD, Kokmen E, editors. Behcet's disease: basic and clinical aspects. New York: Marcel Dekker; 1991. p. 603-12.
47. RB Schwartz SM Bravo RA Klufas, et al. 1995 Cyclosporine neurotoxicity and its relation to hypertensive neuropathy: CT and MR findings in 16 cases Am J Roentgenol 165 627 31 1:STN:280:DyaK2MzntlChtQ%3D%3D
48. Fain O, Huong Du LT, Wechsler B, et al. Pulse cyclophosphamide in Behcet's disease. In: O'Duffy JD, Kokmen E, editors. Behcet's disease: basic and clinical aspects. New York: Marcel Dekker; 1991. p. 569-73.
49. JD O'Duffy K Calamia S Cohen, et al. 1998 Interferon alfa treatment of Behcet's disease J Rheumatol 25 1938 44 9779847 (Pubitemid 28459307)
50. CC Zoboulis CE Orfanos 1998 Treatment of Adamantiades-Behcet's disease with systemic interferon alfa J Rheumatol 134 1010 6 (Pubitemid 28385325)
51. I Kotter AK Eckstein N Stubiger M Zierhut 1998 Treatment of ocular symptoms of Behcet's disease with interferon alfa-2a: a pilot study Br J Ophthalmol 82 488 94 9713053 10.1136/bjo.82.5.488 1:STN:280:DyaK1cznvVKktw%3D%3D
52. I Tugal Tutkun E Guney-Tefekli M Urgancioglu 2006 Results of interferon alfa therapy in patients with Behcet uveitis Graefes Arch Clin Exp Ophthalmol 244 742 6 16205935 10.1007/s00417-005-0137-x (Pubitemid 43923197)
53. M Calguneri AM Onat MA Ozturk, et al. 2005 Transverse myelitis in a patient with Behcet's disease: favorable outcome with a combination of interferon-alpha Clin Rheumatol 24 64 6 15517447 10.1007/s10067-004-0944-1 (Pubitemid 40214803)
54. A Kiyat G Akman-Demir P Serdaroglu M Eraksoy 2002 Behcet's disease: MS-like manifestation. 12th meeting of European neurological society, Berlin 2002 J Neurol 249 Suppl 1 I/165
55. V Hamuryudan C Mat S Saip, et al. 1998 Thalidomide in the treatment of the mucocutaneous lesions of the Behcet's syndrome. A randomized, double-blind, placebo controlled trial Ann Intern Med 128 443 50 9499327 1:CAS:528: DyaK1cXitFeltLg%3D
56. PP Sfikakis 2010 The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions Curr Dir Autoimmun 11 180 210 20173395 10.1159/000289205 1:CAS:528:DC%2BC3cXnvFWmsb8%3D This article is a comprehensive review on the use of biologic TNF antagonists in clinical practice, including their types, approved indications and dosages, and their use in different chronic, noninfectious inflammatory diseases
57. PP Sfikakis 2002 Behcet's disease: a new target for anti-tumour necrosis factor treatment Ann Rheum Dis 61 Suppl 2 ii51 3 12379622
58. S Ohno S Nakamura S Hori M Shimakawa H Kawashima M Mochizuki S Sugita S Ueno K Yoshizaki G Inaba 2004 Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis J Rheumatol 31 1362 8 15229958 1:CAS:528:DC%2BD2cXmtlSlt7o%3D (Pubitemid 38879203)
59. I Tugal Tutkun A Mudun M Urgancioglu, et al. 2005 Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behcet's disease. An open label trial Arthritis Rheum 52 2478 84 16052571 10.1002/art.21231 1:CAS:528:DC%2BD2MXpslGht7s%3D (Pubitemid 41117435)
60. J-P Stugen 2008 Tumor necrosis factor antagonists and neuropathy Muscle Nerve 37 281 92 10.1002/mus.20924 (Pubitemid 351304787)
61. E Yekeler A Tunaci M Tunaci, et al. 2005 Successful medical treatment of abdominal aortic aneurysms with Behcet's disease: imaging findings Australas Radiol 49 182 4 15845063 10.1111/j.1440-1673.2005.01373.x 1:STN:280: DC%2BD2M3htV2msg%3D%3D (Pubitemid 40646320)
62. E Robenshtok I Krause 2004 Arterial involvement in Behçet's disease-the search for new treatment strategies Isr Med Assoc J 6 3 162 3 15055273 (Pubitemid 38380194)
63. A Sayed H Elwan F Fouad, et al. 2010 Behcet extracranial carotid aneurysms: is there still a role for ligation? Eur Vasc Endovasc Surg 39 17 22 10.1016/j.ejvs.2009.09.020 1:STN:280:DC%2BC3c%2FpvF2qtg%3D%3D
64. X Berard JM Corpataux H Taoufiq, et al. 2010 Don't trust a vein graft to treat carotid aneurysm in patients with Behcet's disease J Vasc Surg 52 471 4 20670779 10.1016/j.jvs.2010.03.028
65. O Kizilkilic S Albayram I Adaletli, et al. 2003 Endovascular treatment of Behcet's disease-associated intracranial aneurysms: report of two cases and review of the literature Neuroradiology 45 328 34 12690419 (Pubitemid 36656625)
66. Siva A, Altintas A. Neuro-Behcet syndrome. In: Said G, editor. Intravenous immunoglobulins in the treatment of neurological disorders. London: Martin Dunitz Publishers; 2000. p. 115-26.
67. T Igarashi Y Ishigatsubo S Ohno, et al. 1994 Central nervous system toxicity related to FK 506 in patients with Behcet's disease Ann Rheum Dis 53 350 1 7517134 10.1136/ard.53.5.350 1:STN:280:DyaK2c3ovVOjsw%3D%3D (Pubitemid 24164984)
68. AM Marmont F Gualandi G Piaggio, et al. 2006 Allogeneic bone marrow transplantation (BMT) for refractory Behçet's disease with severe CNS involvement Bone Marrow Transplant 37 1061 3 16633360 10.1038/sj.bmt.1705372 1:STN:280:DC%2BD283nslCgsw%3D%3D
69. A De Cata D Intiso M Bernal, et al. 2007 Prolonged remission of neuro-Behcet's disease following autologous transplantation Int J Immunopathol Pharmacol 20 91 6 17346431 (Pubitemid 46506879)
70. Hamuryudan V, Kötter I. Medical management of Behçet's syndrome. In: YazIcI Y, YazIcI H, editors. Behçet's syndrome; Springer; 2010. p. 317-38. This chapter presents a comprehensive and updated review of all treatments used for each systemic manifestation of Behçet's disease and the current management issues.
71. I Tugal Tutkun SHIELD Study Group 2010 AIN 457, a fully human monoclonal anti-interleukin-17A monoclonal antibody, for the adjunctive treatment of posterior segment uveitis secondary to Behcet's disease: the SHIELD study Clin Exp Rheumatol 28 Suppl 60 S111
72. A Gul B Artim-Esen A Solinger L Giustino I Tugal-Tutkun 2010 Safe, rapid onset and sustained biological activity of IL-1beta regulating antibody XOMA 052 in resistant uveitis of Behcet's disease: preliminary results of a pilot trial. 2010 abstract Clin Exp Rheumatol 28 Suppl 60 S130
73. G Akman-Demir P Serdaroglu 2002 Neuro-Behçet's disease: a practical approach to diagnosis and treatment Pract Neurol 2 340 57 10.1046/j.1474-7766.2002.00105.x